Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06493409
- Locations
- 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT05458102
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC., Miami, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC., Long Beach, California, United States
🇺🇸Triple O Research Institute, P.A., West Palm Beach, Florida, United States
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT04865419
- Locations
- 🇰🇷
Research Site, Busan, Korea, Republic of
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Dokuz Eylul University
- Target Recruit Count
- 62
- Registration Number
- NCT04743544
- Locations
- 🇹🇷
Dokuz Eylul University Hospital, İzmir, Turkey
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 26
- Registration Number
- NCT04551963
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole
- Conditions
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Dokuz Eylul University
- Target Recruit Count
- 34
- Registration Number
- NCT04547335
- Locations
- 🇹🇷
Dokuz Eylul University Hospital, İzmir, Turkey
Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT03827278
- Locations
- 🇨🇳
Guangxi Medical University, Nanning, Guangxi, China
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03672292
- Locations
- 🇩🇪
Universitaetsklinikum Koeln, Klinisches Studienzentrum 2 für Infektiologie, Klinik I für Innere Medizin Kerpener Str. 62, Bettenhaus Ebene 15 Raum 64, Köln, Germany
🇧🇪Hematology Department AZ Sint-Jan Brugge - Oostende AV Campus Brugge Ruddershove 10 8000, Brugge, Belgium
🇨🇦University Health Network at the University of Toronto, Toronto, Ontario, Canada
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 18
- Registration Number
- NCT03515382
- Locations
- 🇬🇧
Quotient Sciences Limited, Ruddington, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.